Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Pichler, M; Lautsch, D; Adler, C; Bögl, K; Drexel, H; Eber, B; Fauer, C; Föchterle, J; Föger, B; Gansch, K; Grafinger, P; Lechleitner, M; Ludvik, B; Maurer, G; Mörz, R; Paulweber, B; Pfeiffer, KP; Prager, R; Stark, G; Toplak, H; Traindl, O; Weitgasser, R.
Are there differences in LDL-C target value attainment in Austrian federal states? Yes!
Wien Med Wochenschr. 2013; 163(23-24):528-535 Doi: 10.1007/s10354-013-0219-z [OPEN ACCESS]
PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Toplak Hermann
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Low density lipoprotein (LDL-C) levels determine the cardiovascular risk. Previous studies indicated an LDL-C target attainment of around 50%, but no Austrian wide analysis on results for the federal states was available. We therefore sought to detect potential differences. Open-label, non-interventional, longitudinal study, registered: www.clinicaltrials.gov NCT 01381679. In all, 746 statin treated patients not at LDL-C goal received intensified therapy for 12 months. The sample was split into nine subgroups, representing the federal states of Austria.We detected an east-west gradient for baseline LDL-C. Individual target values were achieved by 37.2% (range: 26.1-57.7%). After 12 months, LDL-C < 70 mg/l was achieved by 13.5% (5.9-38.5%). Univariate ANCOVA retrieved significant differences within the states (Upper Austria and Salzburg, p = 0.001 and p = 0.0015, respectively). Furthermore, the capacity of intensified lipid lowering therapy applied in practice was as high as -42% as compared to previous standard therapy (additional LDL-C reduction after switch from baseline therapy in Vorarlberg).
Find related publications in this database (using NLM MeSH Indexing): Aged -; Anticholesteremic Agents - therapeutic use; Anticholesteremic Agents -; Azetidines - therapeutic use; Cholesterol, LDL - blood; Cross-Sectional Studies -; Drug Resistance -; Female -; Humans -; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - blood; Longitudinal Studies -; Male -; Middle Aged -; Retreatment -; Topography, Medical -